181229-99-2

Basic information

• Product Name: 3,6-Dihydroxy-8-methyl-8-azabicyclo[3.2.1]octane6-acetate
• Synonyms: 3,6-Dihydroxy-8-methyl-8-azabicyclo[3.2.1]octane6-acetate
• CAS NO: 181229-99-2
• Molecular Formula: C₁₀H₁₇NO₃
• Molecular Weight: 199.25
• Mol File: 181229-99-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,6-Dihydroxy-8-methyl-8-azabicyclo[3.2.1]octane6-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dihydroxy-8-methyl-8-azabicyclo[3.2.1]octane6-acetate(181229-99-2)
• EPA Substance Registry System: 3,6-Dihydroxy-8-methyl-8-azabicyclo[3.2.1]octane6-acetate(181229-99-2)

Safety Data

• Hazardous Substances Data: 181229-99-2(Hazardous Substances Data)

Upstream product

• 17026-42-5 O,O'-dibenzoyl-D-tartaric acid 
• 1100832-64-1 C₁₀H₁₇NO₃*C₁₈H₁₄O₈ 
• 181053-53-2 Acetic acid (1R,6R)-6-[methyl-(2,2,2-trichloro-ethoxycarbonyl)-amino]-cyclohept-2-enyl ester 
• 181053-52-1 ((1R,3R)-3-Hydroxy-cyclohept-4-enyl)-methyl-carbamic acid 2,2,2-trichloro-ethyl ester 
• 181053-48-5 Methyl-((R)-3-oxo-cyclohept-4-enyl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 532-24-1 tropinone 
• 181229-98-1 (-)-6-hydroxytropinone acetate 
• 181053-54-3 Acetic acid (1R,6S)-6-[methyl-(2,2,2-trichloro-ethoxycarbonyl)-amino]-4-oxo-cyclohept-2-enyl ester 

Downstream Products

• 226403-38-9 (6R)-3α-p-chlorobenzoyloxy-6β-acetoxytropane 
• 1100832-60-7 (6R)-3α-p-nitrobenzoyloxy-6β-acetoxytropane 
• 906369-10-6 (6R)-3α-benzenesulfonyloxy-6β-acetoxytropane 
• 97345-82-9 tropane-3α,6β-diol 3-phenylacetate 6-acetate 
• 1423287-20-0 (6R)-3α-orthonitrobenzoyloxy-6β-acetoxytropane 
• 1423287-15-3 (6R)-3α-orthochlorobenzoyloxy-6β-acetoxytropane 

Relevant articles and documents

The absolute configuration plays an important role in muscarinic activity of BGT-A and its analogs

Both enantiomers of 2, 3, and 4, three bioactive analogs of muscarinic agonist BGT-A were prepared respectively and underwent functional studies and radioreceptor binding assays. 6S enantiomers of 2, 3, and 4 showed obvious muscarinic activity, while 6R ones elicited little muscarinic activity by functional studies. Besides, the affinity of 6S enantiomers of 2, 3, and 4 was greatly larger than that of their 6R enantiomers respectively. All these pharmalogical results indicated the 6S configuration was beneficial for the active BGT-A analogs to bind with the muscarinic receptors. The finding was in good agreement with our previous SAR study to BGT-A and its active analogs by computational approach. The understanding to the relationship between muscarinic activity and absolute configuration will provide the basis for successive screening of BGT-A analogs as effective muscarinic agonists or antagonists in clinical use.